REG - Oxford Biomedica PLC - Grant of options

Oxford BioMedicaAnnouncement

24/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231124:nRSX5311Ua&default-theme=true

RNS Number : 5311U  Oxford Biomedica PLC  24 November 2023

Grant of options

 

London, UK - 24 November 2023: Oxford Biomedica plc ("Oxford Biomedica" or
"the Company") (LSE: OXB), a quality and innovation-led cell and gene therapy
CDMO, announces that on 23 November 2023 nil-cost share options over Ordinary
shares of 50 pence each in the Company were granted under the Oxford Biomedica
2015 Long Term Incentive Plan ("LTIP").

 

2023 LTIP Awards

 

 Name of individual  Title                    Number of shares subject to the 2023 LTIP award  Total shares over which options now held  Percentage of current issued share capital under option
 Thierry Cournez     Chief Operating Officer  66,437                                           66,437                                    0.069%

 

The LTIP awards are subject to performance conditions. As set out in the 2022
Directors' Remuneration Report, the performance condition is based on TSR (40%
of the award, assessed over the three years from grant); revenue growth (40%
of the award, assessed over financial years 2023, 2024 and 2025) and strategic
milestones (20% of the award).

 

 

The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Thierry Cournez
 2.  Reason for the notification
 a)  Position/status                          Chief Operating Officer

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Grant of awards over Ordinary Shares under the Company's Long Term Incentive
                                              Plan. No consideration was paid for the grant of awards.
 c)  Price(s) and volumes(s)                  2023 LTIP Award

Price  Volume
                                              Nil    66,437
 d)  Aggregated information

     -    Aggregate volume                    Awards granted over 66,437 shares in total

     -    Price

                                              N/A

 e)  Date of the transaction                  2023-11-23
 f)  Place of the transaction                 Outside of trading venue

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 66,437 shares in total

 

 

N/A

 

e)

Date of the transaction

2023-11-23

f)

Place of the transaction

Outside of trading venue

 

-Ends-

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at
www.oxb.com (https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDGBDBGUDDGXX